Lilly Earnings Call Analysis: Why Zepbound Missed Earnings
Lilly Earnings Call Analysis: Why Zepbound Missed Earnings  
Podcast: On The Pen GLP-1 News
Published On: Thu Oct 31 2024
Description: Send a textDave brings his analysis of the Q3 Eli Lilly earnings call, and how it relates to the future of access to obesity medicine. Also there is an important clarification on the Zepbound savings card that you should not miss.#Zepbound #Mounjaro #TirzepatideVisit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!🤝 Visit Our Sponsors!OTPLinks.com Decoding GLP-1 BookDecoding GLP-1: A Guide for Friends and Family of Those On The PenBuy Here: https://amzn.to/3Dc66d4MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:Venmo: OnThePenCa$h App: ManOnMounjaroBECOME A MEMBER:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join👉 My Amazon Affiliate Store:https://www.amazon.com/shop/manonthemounjaroonthepenWATCH MORE!📺 We're Live M/W/F at 11 central: onthepen.tv 📲 Contact Me: dave@onthepen.comThank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.